DYNAMICS OF CLINICAL LABORATORY PARAMETER IN HIV-INFECTED CHILDREN UNDERGOING DIFFERENT PATTERNS OF INITIAL HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: RANDOMIZED CONTROLLED TRIAL
https://doi.org/10.15690/pf.v13i1.1510
Abstract
Background: Adverse course of HIV infection, rapid development of immunosuppression, severe opportunistic infections and malignant tumors and high mortality substantiate the importance of timely prescription of highly active antiretroviral therapy (HAART). The initial therapy pattern must remain efficient and safe in the long term.
Objective: Our aim was to study effectiveness and safety of different patterns of initial HAART in HIV-infected children.
Methods: The randomized controlled trial involved HIV-infected children aged 1–3 years. Clinical, immunological and virological examinations were conducted before and 12 months after HAART. The initial therapy pattern included 2 nucleoside HIV reverse transcriptase inhibitors — zidovudine and lamivudine. Children were randomized to the groups differing in the third therapy component: lopinavir/ritonavir or nevirapine.
Results: 25 patients were randomized to the lopinavir/ritonavir group, 23 children — to the nevirapine group. After 12 months of treatment, HIV replication suppression (blood viral load < 50 copies/ml) was achieved in 25 (100%) lopinavir/ritonavir group patients and in 16 (70%) nevirapine group patients (p = 0.003). HIV infection did not progress clinically regardless of the pattern. The median number of CD4+CD3+ lymphocytes in the lopinavir/ritonavir group increased from 20.5% (12; 23) to 30% (27; 34) (p < 0,001), in the nevirapine group — from 21.5% (17; 23) to 29% (27; 38) (p < 0.001). Adverse events developed in 13 (27%) children. 3 and 2 children in the lopinavir/ritonavir group suffered from nausea and emesis, respectively. 1 and 1 patient in the nevirapine group suffered from allergic rash and drug-induced hepatitis, respectively.
Conclusion: High effectiveness and safety of lopinavir/ritonavir allow recommending this drug as the third component of the initial HAART pattern for HIV-infected children.
About the Authors
V. B. Denisenko
Rostov State Medical University
Russian Federation
Rostov-on-Don
Russian Federation
Rostov-on-Don
E. N. Simovanyan
Rostov State Medical University
Russian Federation
Rostov-on-Don
Russian Federation
Rostov-on-Don
References
1. Guillen S, Garcia San Miguel L, Resino S, Bellon JM, Gonzalez I, Jimenez de Ory S, Munoz-Fernandez MA, Navarro ML, Gurbindo MD, de Jose MI, Mellado MJ, Martin-Fontelos P, Gonzalez-Tome MI, Martinez J, Beceiro J, Roa MA, Ramos JT. Opportunistic infections and organ-specific diseases in HIV-1-infected children: a cohort study (1990–2006). HIV Med. 2010;11(4):245–252.
2. Nachman SA, Chernoff M, Gona P, Van Dyke RB, Dankner WM, Seage GR, Oleske J, Williams PL. Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. Arch Pediatr Adolesc Med. 2009;163(2):164–171.
3. Симованьян ЭН, Денисенко ВБ. Эффективность применения комбинированной терапии у детей с ВИЧ-инфекцией. Педиат рическая фармакология. 2010;2:41–45.
4. Prasitsuebsai W, Kariminia A, Puthanakit T, Lumbiganon Р., Hansudewechakul S, Siew Moy F, Law M, Kumarasamy N, Razali K, Sirisanthana V, Sohn AH, Chokephaibulkit K. Impact of antiretroviral therapy on opportunistic infections of HIV-infected children in the therapeutic research, education and AIDS training Аsia pediatric HIV observational database. Pediatr Infect Dis. 2014;33(7):747–752.
5. Афонина ЛЮ, Юрин ОГ, Воронин ЕЕ, Фомин ЮА. Особенности АРВТ у детей, больных ВИЧ-инфекцией. В кн.: ВИЧ-инфекция и СПИД. Национальное руководство. Под ред. ВВ Покровского. М.: ГЭОТАР-Медиа. 2013. С. 345–360.
6. Buchholz B, Hien S, Weichert S, Tenenbaum T. Pediatric aspects of HIV1-infection — an over view. Minerva Pediatr. 2010; 62(4):371–387.
7. Lodha R, Manglani M. Antiretroviral therapy in children: recent advances. Indian J Pediatr. 2012;79(12):1625–1633.
8. Покровский ВИ, Покровский ВВ, Юрин ОГ. Клиническая классификация ВИЧ-инфекции. Эпидемиология и инфекционные болезни. 2001;1:7–10.
9. Croxtall JD, Perry CM. Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection. Drugs. 2010;70(14): 1885–1915.
10. Бартлетт Дж, Галлант Дж, Фам П. Клинические аспекты ВИЧ-инфекции, 2012. М.: Р. Валент. 2012. 528 с.
11. Estrela RC, Santoro AB, Barroso PF, Tuyama M, Suarez-Kurtz G. CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects. Clin Pharmacol Ther. 2008;84(2):205–207.
12. Хоффманн К, Рокштро ЮК. Лечение ВИЧ-инфекции, 2011. М.: Р. Валент. 2011. 736 с.
13. Samuel R, Paredes R, Parboosing R, Moodley P, Gordon M. Minority HIV-1 drug-resistant mutations and prevention of motherto-child transmission: perspectives for resource-limited countries. AIDS Rev. 2014;16(4):187–198.
Review
For citations:
Denisenko V.B., Simovanyan E.N. DYNAMICS OF CLINICAL LABORATORY PARAMETER IN HIV-INFECTED CHILDREN UNDERGOING DIFFERENT PATTERNS OF INITIAL HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: RANDOMIZED CONTROLLED TRIAL. Pediatric pharmacology. 2016;13(1):22-26. https://doi.org/10.15690/pf.v13i1.1510
Views:
887
Email this article 